Innovations in Oncology: Focus on Renal Cell Carcinoma

Program Description:

The number of pharmacologic treatment options for clear cell renal cancer, including both immunotherapies and novel targeted therapies, has recently expanded and is expected to continue to grow. These new options offer promise for improved outcomes but also complicate the selection of treatment regimens for patients, particularly for second- and third-line therapies. Additional promising therapies are currently in the pipeline, with a variety of new pathways and treatment approaches under investigation. During this session, presenters will provide an overview of recent developments in the pharmacologic treatment of renal cancer and explore emerging innovations. Potential roles in therapy, including patient factors to consider when individualizing treatment decisions, will be discussed.  

Learning Objectives:

At the completion of this knowledge-based activity, participants should be able to:

Describe the incidence of renal cancer and current treatment landscape for advanced or metastatic clear cell renal cancer.

Identify promising emerging treatment options for patients with for advanced or metastatic clear cell renal cancer and their mechanisms of action.

Describe the potential impact of emerging treatment options on for advanced or metastatic clear cell renal cancer treatment guidelines and recommendations, including sequencing considerations.



Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP

Clinical Professor

UConn School of Pharmacy/UConn Health Carole & Ray Neag Comprehensive Cancer Center

Storrs Manfld, CT


Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth


Coconut Creek, FL

Schedule of Educational Activity:

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN: 0233-9999-21-037-H01-P  • Activity Type: Knowledge-Based
Contact Hours: 0.5
Release Date: October 7, 2021 •  Expiration Date: December 31, 2022
Activity Fee: Free for Members and Non-Members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2021 Virtual.CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

Commercial Support:

This educational activity is supported by unrestricted educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-9999-21-037-H01-P 0.5 Contact Hours October 07, 2021 - December 31, 2022